950596-58-4

Basic information

• Product Name: 2-Amino-4,5-bis(2-methoxyethoxy)benzonitrile
• Synonyms: 2-Amino-4,5-bis(2-methoxyethoxy)benzonitrile;Erlotinib Impurity 21
• CAS NO: 950596-58-4
• Molecular Formula: C₁₃H₁₈N₂O₄
• Molecular Weight: 266.29
• EINECS: 1308068-626-2
• Mol File: 950596-58-4.mol
• Article Data: 8

Chemical Properties

• Melting Point: 73-77 °C
• Boiling Point: 445.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 1.85±0.10(Predicted)
• CAS DataBase Reference: 2-Amino-4,5-bis(2-methoxyethoxy)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4,5-bis(2-methoxyethoxy)benzonitrile(950596-58-4)
• EPA Substance Registry System: 2-Amino-4,5-bis(2-methoxyethoxy)benzonitrile(950596-58-4)

Safety Data

• Hazardous Substances Data: 950596-58-4(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 950596-58-4 differently. You can refer to the following data:
1. 2-((4-Chloro-7-(2-methoxyethoxy)quinazolin-6-yl)oxy)ethanol is an impurity if Erlotinib (E625008) a EGFR-targeted drug in the treatment of non-small cell lung cancer.
2. 2-Amino-4,5-bis(2-methoxyethoxy)benzonitrile is an impurity of Erlotinib (E625008), a EGFR-targeted drug in the treatment of non-small cell lung cancer. EGFR small tyrosine kinase inhibitor that shows most substantial effect on tumor growth inhibition and animal survival.

Upstream product

• 99-50-3 3,4-Dihydroxybenzoic acid 
• 819813-71-3 3,4-bis(2-methoxyethoxy)-benzoic acid 
• 1418289-91-4 3,4-bis(2-methoxyethoxy)-benzamide 
• 80407-68-7 3,4-bis(2-methoxyethoxy)-benzonitrile 
• 236750-65-5 4,5-bis(2-methoxyethoxy)-2-nitrobenzonitrile 

Downstream Products

• 183321-74-6 erlotinib 
• 950596-59-5 N′-[2-cyano-4,5-{bis(2-methoxyethoxy)phenyl}]-N,N-dimethylformamidine 
• 1246445-24-8 erlotinib trifluoroacetate 
• 183319-69-9 erlotinib hydrochloride 
• 766497-25-0 N-(3-trimethylsilyl-ethynyl)-6,7-bis(2-methoxyethoxy)-4-quinolyl-amine 
• 899830-10-5 N-(3-ethynyl phenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine 

Relevant articles and documents

METHOD AND CATALYST FOR PREPARING ANILINE COMPOUNDS AND USE THEREOF

The present invention provides a method for preparing aniline compounds, and also provides a kind of catalyst and use thereof. This method for synthesizing an aniline compound in the invention includes following steps: use molybdenum oxide and activated carbon as catalyst, hydrazine hydrate as reducing agent, then reduce aromatic nitro compounds to aniline compounds. This method is green and high efficiency, and easy to be applied in industry.

Method for synthesizing erlotinib intermediate with microchannel reactor

The invention discloses a method for synthesizing an erlotinib intermediate with a microchannel reactor, belongs to the field of synthesis of anti-tumor drugs in organic synthesis and solves the problems of low yield, poor purity, high energy consumption,

An improved convergent approach for synthesis of erlotinib, a tyrosine kinase inhibitor, via a ring closure reaction of phenyl benzamidine intermediate

An improved convergent and economical method has been developed for the synthesis of erlotinib, a 4-anilinoquinazoline and an EGFR-tyrosine kinase inhibitor for treatment of non-small-cell lung cancer. The final two steps for the formation of this 4-anilinoquinazoline from suitable 2-aminobenzonitrile intermediate and 3-ethynylaniline were modified and were performed in a simple one-pot reaction. The ring-closing mechanism for the formation of erlotinib from the suitable formamidine intermediate and 3-ethynylaniline was investigated and determined to proceed via the formation of phenyl benzamidine intermediate rather than involving Dimroth rearrangement reported earlier. The new benzamidine intermediate was isolated for the first time and characterized. Copyright